Johnson & Johnson (NYSE:JNJ) Shares Acquired by Avantax Planning Partners Inc.

Avantax Planning Partners Inc. boosted its position in Johnson & Johnson (NYSE:JNJ) by 4.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 44,955 shares of the company’s stock after purchasing an additional 1,717 shares during the period. Avantax Planning Partners Inc.’s holdings in Johnson & Johnson were worth $7,455,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Lantz Financial LLC lifted its stake in Johnson & Johnson by 3.3% during the first quarter. Lantz Financial LLC now owns 11,974 shares of the company’s stock valued at $1,986,000 after purchasing an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at $453,000. Horan Securities Inc. boosted its stake in shares of Johnson & Johnson by 1.3% during the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock worth $1,038,000 after acquiring an additional 90 shares in the last quarter. State of Wyoming boosted its stake in shares of Johnson & Johnson by 205,580.0% during the 4th quarter. State of Wyoming now owns 10,284 shares of the company’s stock worth $1,487,000 after acquiring an additional 10,279 shares in the last quarter. Finally, Joel Isaacson & Co. LLC grew its holdings in shares of Johnson & Johnson by 3.5% in the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock worth $12,294,000 after acquiring an additional 2,526 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Up 0.2%

NYSE:JNJ opened at $155.90 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The company has a market capitalization of $375.11 billion, a P/E ratio of 17.34, a P/E/G ratio of 2.36 and a beta of 0.41. The stock’s 50 day moving average price is $153.68 and its 200 day moving average price is $154.09. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. On average, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.34%. The ex-dividend date of this dividend was Tuesday, May 27th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s dividend payout ratio is 57.84%.

Analysts Set New Price Targets

Several brokerages have recently commented on JNJ. Leerink Partners downgraded Johnson & Johnson from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Sanford C. Bernstein restated a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Leerink Partnrs cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 13th. Benchmark upgraded shares of Johnson & Johnson to a “strong-buy” rating in a report on Thursday, April 24th. Finally, Wall Street Zen raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 21st. Eleven analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.